TY - JOUR
T1 - Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic african americans with HIV infection
AU - Lai, Hong Chen
AU - Gerstenblith, Gary
AU - Fishman, Elliot K.
AU - Brinker, Jeffrey
AU - Kickler, Thomas
AU - Tong, Wenjing
AU - Bhatia, Sundeepan
AU - Hong, Tai
AU - Chen, Shaoguang
AU - Li, Ji
AU - Detrick, Barbara
AU - Lai, Shenghan
N1 - Funding Information:
Financial support. This work was supported by grants from the National Institute on Drug Abuse, National Institutes of Health (NIH R01-DA12777, DA25524, and DA15020). Potential conflicts of interest. All authors: No reported conflicts.
PY - 2012/6/15
Y1 - 2012/6/15
N2 - Background. Growing evidence suggests that vitamin D deficiency Is associated with clinical coronary artery disease (CAD). The relationship between vitamin D deficiency and subclinical CAD in HIV-infected individuals is not well-characterized.Methods.Computed tomographic (CT) coronary angiography was performed using contrast-enhanced 64-slice multidetector CT imaging, and vitamin D levels and the presence of traditional and novel risk factor for CAD were obtained in 674 HIV-infected African American (AA) participants aged 25-54 years in Baltimore, MD, without symptoms/clinical evidence of CAD.Results.The prevalence of vitamin D deficiency (25-hydroxy vitamin D <10 ng/mL) was 20.0 (95 confidence interval [CI], 16.9-23.1). Significant (≥50) coronary stenosis was present in 64 (9.5) of 674 participants. Multiple logistic regression analysis revealed that male gender (adjusted odds ratio [OR], 2.19; 95 CI, 1.17-4.10), diastolic BP ≥85 mmHg (adjusted OR: 1.94, 95 CI: 1.02-3.68), low-density lipoprotein cholesterol ≥100 mg/dL (adjusted OR, 1.95; 95 CI, 1.13-3.36), cocaine use for ≥15 years (adjusted OR, 1.77; 95 CI, 1.01-3.10), use of antiretroviral therapies for ≥6 months (adjusted OR, 2.26; 95 CI, 1.17-4.36), year of enrollment after 2005 (adjusted ORs for 2006-2007, 2008-2009, and 2010 were 0.32 [95 CI, 0.13-0.76], 0.26 [95 CI, 0.12-0.56], and 0.32 (95 CI, 0.15-0.65], respectively), and vitamin D deficiency (adjusted OR, 2.28; 95 CI, 1.23-4.21) were independently associated with significant coronary stenosis.Conclusions.Both vitamin D deficiency and silent CAD are prevalent in HIV-infected AAs. In addition to management of traditional CAD risk factors and substance abuse, vitamin D deficiency should be evaluated in HIV-infected AAs. These data support the conduct of a prospective trial of vitamin D in this high-risk patient population.
AB - Background. Growing evidence suggests that vitamin D deficiency Is associated with clinical coronary artery disease (CAD). The relationship between vitamin D deficiency and subclinical CAD in HIV-infected individuals is not well-characterized.Methods.Computed tomographic (CT) coronary angiography was performed using contrast-enhanced 64-slice multidetector CT imaging, and vitamin D levels and the presence of traditional and novel risk factor for CAD were obtained in 674 HIV-infected African American (AA) participants aged 25-54 years in Baltimore, MD, without symptoms/clinical evidence of CAD.Results.The prevalence of vitamin D deficiency (25-hydroxy vitamin D <10 ng/mL) was 20.0 (95 confidence interval [CI], 16.9-23.1). Significant (≥50) coronary stenosis was present in 64 (9.5) of 674 participants. Multiple logistic regression analysis revealed that male gender (adjusted odds ratio [OR], 2.19; 95 CI, 1.17-4.10), diastolic BP ≥85 mmHg (adjusted OR: 1.94, 95 CI: 1.02-3.68), low-density lipoprotein cholesterol ≥100 mg/dL (adjusted OR, 1.95; 95 CI, 1.13-3.36), cocaine use for ≥15 years (adjusted OR, 1.77; 95 CI, 1.01-3.10), use of antiretroviral therapies for ≥6 months (adjusted OR, 2.26; 95 CI, 1.17-4.36), year of enrollment after 2005 (adjusted ORs for 2006-2007, 2008-2009, and 2010 were 0.32 [95 CI, 0.13-0.76], 0.26 [95 CI, 0.12-0.56], and 0.32 (95 CI, 0.15-0.65], respectively), and vitamin D deficiency (adjusted OR, 2.28; 95 CI, 1.23-4.21) were independently associated with significant coronary stenosis.Conclusions.Both vitamin D deficiency and silent CAD are prevalent in HIV-infected AAs. In addition to management of traditional CAD risk factors and substance abuse, vitamin D deficiency should be evaluated in HIV-infected AAs. These data support the conduct of a prospective trial of vitamin D in this high-risk patient population.
UR - http://www.scopus.com/inward/record.url?scp=84861521226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861521226&partnerID=8YFLogxK
U2 - 10.1093/cid/cis306
DO - 10.1093/cid/cis306
M3 - Article
C2 - 22423137
AN - SCOPUS:84861521226
SN - 1058-4838
VL - 54
SP - 1747
EP - 1755
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 12
ER -